Summary:

In this issue, Rubinson, Tanaka, and colleagues demonstrate that differences among G12C inhibitors rely on their ability to covalently bind not only G12C mutant KRAS but also NRAS and HRAS, proposing sotorasib as a potent NRAS G12C inhibitor.

See related article by Rubinson et al., p. 727 (6).

©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.